Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Britain Courts Anthropic Amid US Defense Department Dispute 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
NATICK, Mass., Sept. 08, 2016 -- VCANBIO USA Co. Ltd. (VCANBIO USA) and VCANBIO Center for Translational Biotechnology (VCANBIO CTB) today announced that they will host an opening ceremony to celebrate the launch of U.S. operations as subsidiaries of VCANBIO Cell & Engineering Corporation Ltd. (VCANBIO), a company focused on cell therapy and precision medicine.
“Expanding operations into the United States is a momentous occasion for VCANBIO, the largest Chinese biotechnology company and the first company to offer cord blood storage in China,” said Yong Wang, Chairman of VCANBIO USA and VCANBIO Center for Translational Biotechnology. “VCANBIO USA focuses on investing in cell and immunotherapies, while VCANBIO Center for Translational Biotechnology functions as a service entity that fosters partnerships to advance promising new therapies. We are eager to begin building relationships and contributing to the robust biotech community in Massachusetts and the larger United States.”
Following are details of the opening ceremony.
| What: | Ribbon-cutting ceremony, lunch and tour of VCANBIO CTB’s lab | ||
| Who: | Rep. David P. Linsky (D), State Representative for the 5th Middlesex House District | ||
| Jijun Xing, the Counselor Consul of Science and Technology Affairs, the Consulate General of the People’s Republic of China in New York | |||
| Defu Li, Chairman of VCANBIO’s board of directors | |||
| Yong Wang, Vice Chairman of VCANBIO’s board of directors | |||
| Dr. MingYuan Wu, Chief Executive Officer of VCANBIO | |||
| Dr. John Lu, President and Chief Executive Officer of VCANBIO CTB | |||
| When: | Saturday, September 10, 2016, 11:30 a.m. to 3 p.m. | ||
| Where: | VCANBIO USA and VCANBIO CTB corporate office | ||
| 21 Strathmore Road | |||
| Natick, MA 01760 | |||
| RSVP: | If you are a journalist interested in attending the event, please contact Eric Chen at [email protected]. | ||
The ceremony will continue in the evening with a celebratory dinner at the Museum of Fine Arts in Boston.
About VCANBIO USA and VCANBIO Center for Translational Biotechnology
VCANBIO USA Co. Ltd. and VCANBIO Center for Translational Biotechnology are U.S. subsidiaries owned by VCANBIO Cell & Engineering Corporation Ltd. VCANBIO USA is focused on investing in cell and immunotherapies in North America. VCANBIO CTB is a service entity that identifies promising new therapies at various stages of clinical translation and provides partners with the expertise and resources necessary to efficiently develop the therapies. VCANBIO CTB’s scientific advisory board is comprised of esteemed scientists with expertise in stem cells, hematology, cancer and more. The companies’ corporate offices and labs are located in Natick, MA.
CONTACT: Eric Chen (518) 256-7558 [email protected]
